📣 VC round data is live. Check it out!

iRhythm Holdings Valuation Multiples

Discover revenue and EBITDA valuation multiples for iRhythm Holdings and similar public comparables like Merit Medical Systems, Envista Holdings, Medacta Group, Jiangsu Yuyue Medical and more.

iRhythm Holdings Overview

About iRhythm Holdings

iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.


Founded

2006

HQ

United States

Employees

2.4K

Financials (LTM)

Revenue: $803M
EBITDA: $86M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

iRhythm Holdings Financials

iRhythm Holdings reported last 12-month revenue of $803M and EBITDA of $86M.

In the same LTM period, iRhythm Holdings generated $570M in gross profit, $86M in EBITDA, and had net loss of ($26M).

Revenue (LTM)


iRhythm Holdings P&L

In the most recent fiscal year, iRhythm Holdings reported revenue of $747M and EBITDA of $69M.

iRhythm Holdings is unprofitable as of last fiscal year, with gross margin of 71%, EBITDA margin of 9%, and net margin of (6%).

See analyst estimates for iRhythm Holdings
LTMLast FY202320242025202620272028
Revenue$803M$747M$493M$592M$747M
Gross Profit$570M$527M$332M$408M$527M
Gross Margin71%71%67%69%71%
EBITDA$86M$69M($97M)($74M)($4M)
EBITDA Margin11%9%(20%)(13%)(1%)
EBIT Margin(4%)(7%)(23%)(19%)(7%)
Net Profit($26M)($45M)($123M)($113M)($45M)
Net Margin(3%)(6%)(25%)(19%)(6%)
Net Debt-$413M---

Financial data powered by Morningstar, Inc.

iRhythm Holdings Stock Performance

iRhythm Holdings has current market cap of $4B, and enterprise value of $4B.

Market Cap Evolution


iRhythm Holdings' stock price is $113.90.

iRhythm Holdings share price decreased by 12.0% in the last 30 days, and by 18.9% in the last year.

iRhythm Holdings has an EPS (earnings per share) of $-1.36.

See more trading valuation data for iRhythm Holdings
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$4B0.0%-12.0%-14.8%-18.9%$-1.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

iRhythm Holdings Valuation Multiples

iRhythm Holdings trades at 4.9x EV/Revenue multiple, and 45.7x EV/EBITDA.

See NTM and 2027E valuation multiples for iRhythm Holdings

EV / Revenue (LTM)


iRhythm Holdings Financial Valuation Multiples

As of May 31, 2026, iRhythm Holdings has market cap of $4B and EV of $4B.

iRhythm Holdings has a P/E ratio of (143.2x).

LTMLast FY202320242025202620272028
EV/Revenue4.9x5.3x8.0x6.6x5.3x
EV/EBITDA45.7x56.9x(40.5x)(52.9x)n/m
EV/EBIT(133.1x)(80.5x)(34.4x)(34.2x)(74.1x)
EV/Gross Profit6.9x7.4x11.8x9.6x7.4x
P/E(143.2x)(84.0x)(30.3x)(33.0x)(84.0x)
EV/FCF94.2x113.6x(43.3x)(86.1x)113.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified iRhythm Holdings Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

iRhythm Holdings Margins & Growth Rates

iRhythm Holdings grew revenue by 18% and EBITDA by 59% in the last fiscal year.

In the most recent fiscal year, iRhythm Holdings reported gross margin of 71%, EBITDA margin of 9%, and net margin of (6%).

See estimated margins and future growth rates for iRhythm Holdings

iRhythm Holdings Margins

Last FY202420252026202720282029
Gross Margin71%69%71%72%
EBITDA Margin9%(13%)(1%)12%
EBIT Margin(7%)(19%)(7%)(0%)
Net Margin(6%)(19%)(6%)(0%)
FCF Margin5%(8%)5%7%

iRhythm Holdings Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth18%20%26%18%
Gross Profit Growth20%23%29%20%
EBITDA Growth59%(23%)(95%)(2868%)
EBIT Growth(95%)1%(54%)(96%)
Net Profit Growth(100%)(8%)(61%)(100%)
FCF Growth81%(50%)(176%)81%

Data powered by FactSet, Inc. and Morningstar, Inc.

iRhythm Holdings Operational KPIs

iRhythm Holdings' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

iRhythm Holdings' Rule of 40 is 30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

iRhythm Holdings' Rule of X is 57% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for iRhythm Holdings
LTMLast FY202320242025202620272028
Rule of 4028%30%---
Bessemer Rule of X53%57%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.2M---
R&D Expenses to Revenue11%12%12%18%12%
Opex to Revenue-78%91%88%78%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

iRhythm Holdings Competitors

iRhythm Holdings competitors include Merit Medical Systems, Envista Holdings, Medacta Group, Jiangsu Yuyue Medical, Ottobock, Rigaku, LivaNova, Lepu Medical Technology, ICU Medical and Minimed Group.

Most iRhythm Holdings public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Merit Medical Systems2.7x2.6x10.8x10.6x
Envista Holdings1.6x1.6x11.7x11.2x
Medacta Group4.9x4.7x17.1x16.8x
Jiangsu Yuyue Medical3.2x3.1x13.1x15.9x
Ottobock2.8x2.7x15.3x10.7x
Rigaku6.9x6.7x29.8x28.2x
LivaNova2.8x2.7x12.2x11.6x
Lepu Medical Technology3.8x3.7x12.3x12.2x

This data is available for Pro users. Sign up to see all iRhythm Holdings competitors and their valuation data.

Start Free Trial

iRhythm Holdings Funding History

Before going public, iRhythm Holdings raised $263M in total equity funding, across 3 rounds.


iRhythm Holdings Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Aug-20Secondary - public-$220M-iRhythm Technologies is a digital healthcare company focused on advancing cardiac care through wearable biosensor devices worn up to 14 days, cloud-based analytics, and proprietary algorithms for arrhythmia detection. On August 21, 2020, the company closed an upsized follow-on public offering of 1,257,142 shares of common stock at $175.00 per share, generating gross proceeds of approximately $220 million before underwriting discounts and expenses. The net proceeds were intended for growth initiatives, working capital, general corporate purposes, and sales force expansion. The offering was led by J.P. Morgan and Morgan Stanley as joint book-runners, with Citigroup, Truist Securities, and William Blair as co-managers. For the second quarter of 2020, ended June 30, iRhythm reported net revenue of $50.9 million, gross profit of $35.4 million, and cost of revenue of $15.5 million.
May-14Series ENorwest; Novo Holdings$27M-iRhythm Technologies, a healthcare information services company founded in 2006, specializes in cardiac monitoring solutions through its flagship ZIO Service for long-term continuous cardiac monitoring of patients with suspected arrhythmia. The ZIO Service had been used with nearly 250,000 patients across over 800 institutions by May 2014, with coverage from leading public and private insurers since its 2011 launch. In May 2014, iRhythm closed a $17 million Series E financing round led by Novo A/S, with participation from Norwest Venture Partners, which had led the company's Series D round. The company planned to use the proceeds to accelerate market growth for the ZIO Service, expand technology development, and establish additional clinical evidence supporting its solution. By October 2016, iRhythm completed its initial public offering at $107 million, having raised a total of $99.03 million across 12 funding rounds prior to going public. The company had grown to over 1,000 employees by the time of its later funding activities.
Apr-13Series DKaiser Permanente Ventures; New Leaf Venture Partners; Norwest; Stanford University; Synergy Life Science Partner$16M-iRhythm Technologies, a Stanford University spin-out medical device firm, raised $16 million in a Series D round on April 13, 2013, led by Norwest Venture Partners with participation from Kaiser Permanente Ventures, New Leaf Venture Partners, Synergy Life Science Partners, and Stanford University. The funding supports expansion of commercial efforts and acceleration of new product development for its flagship Zio System, which diagnoses and monitors cardiac arrhythmias and has reported over 20 million hours of patient data since its 2011 introduction. Casper de Clercq from Norwest joined the board. The company, founded in 2006 and based in San Francisco, had previously raised a total of $52 million, including a $6.5 million Series B in 2009.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About iRhythm Holdings

When was iRhythm Holdings founded?iRhythm Holdings was founded in 2006.
Where is iRhythm Holdings headquartered?iRhythm Holdings is headquartered in United States.
How many employees does iRhythm Holdings have?As of today, iRhythm Holdings has over 2K employees.
Is iRhythm Holdings publicly listed?Yes, iRhythm Holdings is a public company listed on Nasdaq.
What is the stock symbol of iRhythm Holdings?iRhythm Holdings trades under IRTC ticker.
When did iRhythm Holdings go public?iRhythm Holdings went public in 2016.
Who are competitors of iRhythm Holdings?iRhythm Holdings main competitors include Merit Medical Systems, Envista Holdings, Medacta Group, Jiangsu Yuyue Medical, Ottobock, Rigaku, LivaNova, Lepu Medical Technology, ICU Medical, Minimed Group.
What is the current market cap of iRhythm Holdings?iRhythm Holdings' current market cap is $4B.
What is the current revenue of iRhythm Holdings?iRhythm Holdings' last 12 months revenue is $803M.
What is the current revenue growth of iRhythm Holdings?iRhythm Holdings revenue growth (NTM/LTM) is 17%.
What is the current EV/Revenue multiple of iRhythm Holdings?Current revenue multiple of iRhythm Holdings is 4.9x.
What is the current EBITDA of iRhythm Holdings?iRhythm Holdings' last 12 months EBITDA is $86M.
What is iRhythm Holdings' EBITDA margin?iRhythm Holdings' last 12 months EBITDA margin is 11%.
What is the current EV/EBITDA multiple of iRhythm Holdings?Current EBITDA multiple of iRhythm Holdings is 45.7x.
What is the current FCF of iRhythm Holdings?iRhythm Holdings' last 12 months FCF is $42M.
What is iRhythm Holdings' FCF margin?iRhythm Holdings' last 12 months FCF margin is 5%.
What is the current EV/FCF multiple of iRhythm Holdings?Current FCF multiple of iRhythm Holdings is 94.2x.
How many companies iRhythm Holdings has acquired to date?iRhythm Holdings hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies iRhythm Holdings has invested to date?iRhythm Holdings hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to iRhythm Holdings

Lists including iRhythm Holdings

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial